Profile data is unavailable for this security.
About the company
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.
- Revenue in USD (TTM)0.00
- Net income in USD-127.69m
- Incorporated2018
- Employees103.00
- LocationErasca Inc3115 Merryfield Row, Third FloorSAN DIEGO 92121United StatesUSA
- Phone+1 (858) 465-6511
- Fax+1 (302) 636-5454
- Websitehttps://www.erasca.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alumis Inc | 22.12m | -245.15m | 3.70bn | 233.00 | -- | 8.06 | -- | 167.48 | -3.85 | -3.85 | 0.3057 | 3.69 | 0.0491 | -- | 9.28 | 131,672.60 | -54.44 | -- | -61.16 | -- | -- | -- | -1,108.24 | -- | -- | -- | 0.00 | -- | -- | -- | -89.84 | -- | -- | -- |
| Viking Therapeutics Inc | 0.00 | -359.64m | 3.85bn | 53.00 | -- | 5.99 | -- | -- | -3.18 | -3.18 | 0.00 | 5.57 | 0.00 | -- | -- | 0.00 | -44.29 | -31.71 | -47.32 | -33.62 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -227.05 | -- | -- | -- |
| ACADIA Pharmaceuticals Inc | 1.07bn | 391.00m | 3.89bn | 796.00 | 10.00 | 3.17 | 9.66 | 3.63 | 2.28 | 2.28 | 6.31 | 7.21 | 0.7787 | 3.14 | 9.73 | 1,346,112.00 | 28.42 | 3.92 | 37.60 | 5.17 | 91.69 | 93.59 | 36.49 | 4.59 | 3.71 | -- | 0.00 | 0.00 | 11.87 | 19.39 | 72.66 | -- | 68.65 | -- |
| Gyroscope Therapeutics Holdings Ltd(ADR) | -100.00bn | -100.00bn | 4.02bn | 167.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -70.87 | -- | -58.56 | -- | -- | -- |
| Crinetics Pharmaceuticals Inc | 7.70m | -465.32m | 4.26bn | 594.00 | -- | 3.92 | -- | 553.46 | -4.94 | -4.94 | 0.0818 | 10.38 | 0.006 | -- | 1.71 | 12,956.23 | -36.34 | -36.26 | -38.52 | -38.45 | 66.07 | -- | -6,046.22 | -6,696.84 | 12.30 | -- | 0.00 | -- | 640.71 | 155.27 | -55.93 | -- | 98.71 | -- |
| Scholar Rock Holding Corp | 0.00 | -353.43m | 4.44bn | 196.00 | -- | 17.60 | -- | -- | -3.15 | -3.15 | 0.00 | 2.47 | 0.00 | -- | -- | 0.00 | -119.63 | -45.06 | -144.40 | -51.62 | -- | -- | -- | -1,134.62 | -- | -- | 0.2891 | -- | -- | -- | -48.56 | -- | -49.93 | -- |
| Structure Therapeutics Inc (ADR) | 0.00 | -141.20m | 4.46bn | 220.00 | -- | 2.94 | -- | -- | -2.49 | -2.49 | 0.00 | 21.41 | 0.00 | -- | -- | 0.00 | -11.35 | -18.40 | -11.83 | -19.33 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -15.24 | -- | 185.66 | -- |
| Terns Pharmaceuticals Inc | 0.00 | -94.44m | 4.46bn | 59.00 | -- | 12.95 | -- | -- | -1.03 | -1.03 | 0.00 | 3.25 | 0.00 | -- | -- | 0.00 | -27.78 | -32.69 | -28.92 | -35.03 | -- | -- | -- | -33,013.70 | -- | -- | 0.00 | -- | -- | -- | 1.50 | -- | -45.82 | -- |
| Erasca Inc | 0.00 | -127.69m | 4.50bn | 103.00 | -- | 11.85 | -- | -- | -0.4506 | -0.4506 | 0.00 | 1.23 | 0.00 | -- | -- | 0.00 | -26.90 | -41.53 | -28.68 | -44.78 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -29.28 | -- | -36.84 | -- |
| Amicus Therapeutics, Inc. | 634.21m | -27.11m | 4.51bn | 511.00 | -- | 16.28 | -- | 7.11 | -0.0885 | -0.0885 | 2.05 | 0.8822 | 0.7311 | 0.4196 | 5.86 | 1,241,116.00 | -3.13 | -17.56 | -4.02 | -21.71 | 88.50 | 89.24 | -4.27 | -32.86 | 1.88 | 0.8051 | 0.5888 | -- | 20.05 | 19.44 | 51.68 | -- | 0.424 | -- |
| Apogee Therapeutics Inc | 0.00 | -253.67m | 4.84bn | 196.00 | -- | 7.17 | -- | -- | -4.36 | -4.36 | 0.00 | 9.89 | 0.00 | -- | -- | 0.00 | -36.18 | -- | -37.98 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -116.88 | -- | -- | -- |
| CG Oncology Inc | 2.17m | -151.48m | 4.88bn | 113.00 | -- | 6.58 | -- | 2,243.32 | -2.03 | -2.03 | 0.0292 | 8.78 | 0.0034 | -- | 6.67 | 19,238.94 | -23.63 | -- | -24.51 | -- | 4.09 | -- | -6,967.99 | -- | 22.74 | -- | 0.0043 | -- | 458.33 | -- | -29.85 | -- | -- | -- |
| Celcuity Inc | 0.00 | -162.72m | 5.01bn | 87.00 | -- | 40.07 | -- | -- | -3.67 | -3.67 | 0.00 | 2.70 | 0.00 | -- | -- | 0.00 | -43.45 | -42.61 | -47.58 | -45.75 | -- | -- | -- | -- | -- | -48.30 | 0.7325 | -- | -- | -- | -75.26 | -- | -8.05 | -- |
| Alkermes Plc | 1.48bn | 241.66m | 5.04bn | 2.05k | 21.12 | 2.75 | 18.47 | 3.42 | 1.43 | 1.43 | 8.74 | 10.99 | 0.6498 | 1.04 | 4.08 | 719,950.80 | 10.64 | 10.11 | 13.68 | 13.22 | 86.69 | 84.10 | 16.37 | 15.06 | 3.19 | -- | 0.00 | 0.00 | -5.25 | 7.28 | -35.06 | -- | -0.8671 | -- |
Data as of Mar 02 2026. Currency figures normalised to Erasca Inc's reporting currency: US Dollar USD
33.12%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| T. Rowe Price Investment Management, Inc.as of 31 Dec 2025 | 16.11m | 5.20% |
| Paradigm BioCapital Advisors LPas of 07 Jan 2026 | 15.16m | 4.90% |
| Suvretta Capital Management LLCas of 31 Dec 2025 | 14.50m | 4.68% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 13.50m | 4.36% |
| Logos Global Management LPas of 31 Dec 2025 | 13.00m | 4.20% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 11.38m | 3.68% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 6.17m | 1.99% |
| Geode Capital Management LLCas of 31 Dec 2025 | 4.93m | 1.59% |
| Affinity Asset Advisors LLCas of 31 Dec 2025 | 3.90m | 1.26% |
| Spruce Street Capital LPas of 31 Dec 2025 | 3.89m | 1.26% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
